Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Vardhaman Patel"'
Autor:
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Pierre Nicolas, Wei-Jhih Wang, Matthew J. Colombo, Viktor Chirikov
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1891-1899 (2024)
Abstract Introduction Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate to severe plaque psoriasis in the POETYK PSO-1 and PSO-2 clinical trials. In the study reported here, we aimed to determine the overall 52-we
Externí odkaz:
https://doaj.org/article/1aec112419374b6eb1dbe535de388b5c
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.Objective This study compared the cost per response (CPR) for US patients initi
Externí odkaz:
https://doaj.org/article/f02293324a8649d49be744bac27d627a
Autor:
Tina Bhutani, Sayeli Jayade, Sanika Rege, Hannah Penton, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Lauren Seigel
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experienci
Externí odkaz:
https://doaj.org/article/6a541e87403a42e39eeb760a48781c7a
Autor:
April W. Armstrong, Sayeli Jayade, Sanika Rege, Namita Joshi, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Dipen Patel, Lauren Seigel
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 2, Pp 421-439 (2024)
Abstract Introduction While multiple treatments are available for moderate to severe psoriasis, patient preferences are rarely systematically studied. This study aims to identify factors associated with choice of a new once-daily oral psoriasis treat
Externí odkaz:
https://doaj.org/article/6b79c2089b0742b696b77cee58260ec4
Autor:
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2589-2603 (2023)
Abstract Introduction Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared the long-term efficacy of deucravacitinib and adal
Externí odkaz:
https://doaj.org/article/3acdd55e51df464cb2bdfcb1bfd0b3fc
Autor:
Lana Schmidt, Ching An Wang, Vardhaman Patel, David Davidson, Samaneh Kalirai, Ankita Panda, Lauren Seigel
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 9, Pp 2019-2030 (2023)
Abstract Introduction Apremilast, the first oral targeted treatment for moderate to severe psoriasis, is associated with diarrhea, nausea, and vomiting, which have contributed to treatment discontinuation. This study describes early apremilast discon
Externí odkaz:
https://doaj.org/article/35154e8ccfae43dda6d059f4170caad1
Autor:
Jashin J. Wu, Ching An Wang, Greeta Jobson, David Davidson, Samaneh Kalirai, Julia Zhu, Manasi Suryavanshi, Mayank Mittal, Vardhaman Patel, Lauren Seigel
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Objective This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor. Methods This retrospective cohort study used Optum Clinforma
Externí odkaz:
https://doaj.org/article/5b6db17de9fb40db8013d1b1a84cc912
Autor:
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2605-2607 (2023)
Externí odkaz:
https://doaj.org/article/911358deff724f73b8fd9e91cccd1478
Publikováno v:
Dermatology and Therapy. 13:207-219
This study assessed the comorbidity burden, healthcare resource utilization (HCRU), and costs associated with patients with moderate to severe psoriasis (PsO) compared with a matched cohort of the general population without PsO in the USA.Comorbidity
Autor:
Vardhaman, Patel, Zulkarnain, Pulungan, Anne, Shah, Barton, Jones, Allison, Petrilla, Leticia, Ferri, Xue, Han, Kaleb, Michaud
Publikováno v:
Rheumatology and Therapy. 9:1091-1107
Targeted DMARD (tDMARD) use in patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) may increase whole-body insulin sensitivity. Evidence comparing the T2DM-related clinical and economic impact of abatacept versus other tDMARDs